Literature DB >> 34193486

SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials.

Melanie Calvert1,2,3,4,5, Madeleine King6, Rebecca Mercieca-Bebber7, Olalekan Aiyegbusi8,3, Derek Kyte8, Anita Slade8,4, An-Wen Chan9, E Basch10, Jill Bell11, Antonia Bennett12, Vishal Bhatnagar13, Jane Blazeby14,15, Andrew Bottomley16, Julia Brown17, Michael Brundage18, Lisa Campbell19, Joseph C Cappelleri20, Heather Draper21, Amylou C Dueck22, Carolyn Ells23, Lori Frank24, Robert M Golub25, Ingolf Griebsch26, Kirstie Haywood27, Amanda Hunn28, Bellinda King-Kallimanis13, Laura Martin29, Sandra Mitchell30, Thomas Morel31, Linda Nelson32, Josephine Norquist33, Daniel O'Connor19, Michael Palmer34, Donald Patrick35, Gary Price8, Antoine Regnault36, Ameeta Retzer8, Dennis Revicki37, Jane Scott38, Richard Stephens39, Grace Turner8,4, Antonia Valakas40, Galina Velikova41, Maria von Hildebrand8, Anita Walker8, Lari Wenzel42.   

Abstract

Patient-reported outcomes (PROs) are used in clinical trials to provide valuable evidence on the impact of disease and treatment on patients' symptoms, function and quality of life. High-quality PRO data from trials can inform shared decision-making, regulatory and economic analyses and health policy. Recent evidence suggests the PRO content of past trial protocols was often incomplete or unclear, leading to research waste. To address this issue, international, consensus-based, PRO-specific guidelines were developed: the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)-PRO Extension. The SPIRIT-PRO Extension is a 16-item checklist which aims to improve the content and quality of aspects of clinical trial protocols relating to PRO data collection to minimise research waste, and ultimately better inform patient-centred care. This SPIRIT-PRO explanation and elaboration (E&E) paper provides information to promote understanding and facilitate uptake of the recommended checklist items, including a comprehensive protocol template. For each SPIRIT-PRO item, we provide a detailed description, one or more examples from existing trial protocols and supporting empirical evidence of the item's importance. We recommend this paper and protocol template be used alongside the SPIRIT 2013 and SPIRIT-PRO Extension paper to optimise the transparent development and review of trial protocols with PROs. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  clinical trials; education & training (see medical education & training); protocols & guidelines; statistics & research methods

Mesh:

Year:  2021        PMID: 34193486      PMCID: PMC8246371          DOI: 10.1136/bmjopen-2020-045105

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


  113 in total

1.  Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.

Authors:  Martin R Stockler; Felix Hilpert; Michael Friedlander; Madeleine T King; Lari Wenzel; Chee Khoon Lee; Florence Joly; Nikolaus de Gregorio; José Angel Arranz; Mansoor Raza Mirza; Roberto Sorio; Ulrich Freudensprung; Vesna Sneller; Gill Hales; Eric Pujade-Lauraine
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

2.  Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions.

Authors:  D L Fairclough; D F Cella
Journal:  Qual Life Res       Date:  1996-06       Impact factor: 4.147

3.  Putting patients at the heart of health-care research.

Authors:  Melanie Calvert; Derek Kyte; Maria von Hildebrand; Madeleine King; David Moher
Journal:  Lancet       Date:  2015-03-21       Impact factor: 79.321

4.  PRO data collection in clinical trials using mixed modes: report of the ISPOR PRO mixed modes good research practices task force.

Authors:  Sonya Eremenco; Stephen Joel Coons; Jean Paty; Karin Coyne; Antonia V Bennett; Damian McEntegart
Journal:  Value Health       Date:  2014-07       Impact factor: 5.725

5.  Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.

Authors:  Sandro Pignata; Giovanni Scambia; Gabriella Ferrandina; Antonella Savarese; Roberto Sorio; Enrico Breda; Vittorio Gebbia; Pietro Musso; Luigi Frigerio; Pietro Del Medico; Alessandra Vernaglia Lombardi; Antonio Febbraro; Paolo Scollo; Antonella Ferro; Stefano Tamberi; Alba Brandes; Alberto Ravaioli; Maria Rosaria Valerio; Enrico Aitini; Donato Natale; Laura Scaltriti; Stefano Greggi; Carmela Pisano; Domenica Lorusso; Vanda Salutari; Francesco Legge; Massimo Di Maio; Alessandro Morabito; Ciro Gallo; Francesco Perrone
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

6.  The Mayo Clinic manuscript series relative to the discussion, dissemination, and operationalization of the Food and Drug Administration guidance on patient-reported outcomes.

Authors:  Jeff A Sloan; Michele Y Halyard; Marlene H Frost; Amylou C Dueck; Bonnie Teschendorf; Margaret L Rothman
Journal:  Value Health       Date:  2007 Nov-Dec       Impact factor: 5.725

7.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

8.  Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.

Authors:  Madeleine T King; Emma K Link; Tim J Whelan; Ivo A Olivotto; Ian Kunkler; Antonia Helen Westenberg; Guenther Gruber; Penny Schofield; Boon H Chua
Journal:  Lancet Oncol       Date:  2020-03-20       Impact factor: 41.316

9.  What do these scores mean? Presenting patient-reported outcomes data to patients and clinicians to improve interpretability.

Authors:  Claire F Snyder; Katherine C Smith; Elissa T Bantug; Elliott E Tolbert; Amanda L Blackford; Michael D Brundage
Journal:  Cancer       Date:  2017-01-13       Impact factor: 6.860

10.  The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis.

Authors:  Samantha Cruz Rivera; Derek G Kyte; Olalekan Lee Aiyegbusi; Anita L Slade; Christel McMullan; Melanie J Calvert
Journal:  Health Qual Life Outcomes       Date:  2019-10-16       Impact factor: 3.186

View more
  10 in total

1.  Whole-body photobiomodulation therapy for chronic pain: a protocol for a feasibility trial.

Authors:  Bethany Fitzmaurice; Nicola R Heneghan; Asius Rayen; Andrew Soundy
Journal:  BMJ Open       Date:  2022-06-29       Impact factor: 3.006

2.  Application of Patient-Reported Outcome Measurements in Clinical Trials in China.

Authors:  Hui Zhou; Mi Yao; Xiaodan Gu; Mingrui Liu; Ruifeng Zeng; Qin Li; Tingjia Chen; Wen He; Xiao Chen; Gang Yuan
Journal:  JAMA Netw Open       Date:  2022-05-02

3.  Patient-Reported Outcomes in Kidney Trials: Magnesium, Muscle Cramps, and PROMising Better Care for Kidney Patients.

Authors:  Michelle M Richardson
Journal:  Kidney Med       Date:  2022-01-12

Review 4.  Patient-reported outcomes and target effect sizes in pragmatic randomized trials in ClinicalTrials.gov: A cross-sectional analysis.

Authors:  Shelley Vanderhout; Dean A Fergusson; Jonathan A Cook; Monica Taljaard
Journal:  PLoS Med       Date:  2022-02-08       Impact factor: 11.069

5.  The SPIRIT Checklist-lessons from the experience of SPIRIT protocol editors.

Authors:  Riaz Qureshi; Alexander Gough; Kirsty Loudon
Journal:  Trials       Date:  2022-04-27       Impact factor: 2.728

6.  Evaluation of the Distal Radial Approach in percutaneous coronary interventions. Controlled, randomized non-inferiority trial.

Authors:  Ahmed Ben Amara; Aymen Noamen; Yassine Anouar; Sarra Chenik; Nadhem Hajlaoui; Wafa Fehri
Journal:  Tunis Med       Date:  2022 mars

Review 7.  A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020.

Authors:  Maria Manuel Teixeira; Fábio Cardoso Borges; Paula Sousa Ferreira; João Rocha; Bruno Sepodes; Carla Torre
Journal:  Front Med (Lausanne)       Date:  2022-08-12

8.  Improving the patient-reported outcome sections of clinical trial protocols: a mixed methods evaluation of educational workshops.

Authors:  Madeleine T King; Margaret-Ann Tait; Rachel Campbell; Fabiola Müller; Claudia Rutherford; Corinna Beckmore; Sophie Chima; Danette Langbecker; Joanne Shaw; Rebecca Mercieca-Bebber
Journal:  Qual Life Res       Date:  2022-05-12       Impact factor: 3.440

9.  Listening to the Patient Voice Adds Value to Cancer Clinical Trials.

Authors:  Michael D Brundage; Norah L Crossnohere; Jennifer O'Donnell; Samantha Cruz Rivera; Roger Wilson; Albert W Wu; David Moher; Derek Kyte; Bryce B Reeve; Alexandra Gilbert; Ronald C Chen; Melanie J Calvert; Claire Snyder
Journal:  J Natl Cancer Inst       Date:  2022-10-06       Impact factor: 11.816

10.  Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE.

Authors:  Anthony Muchai Manyara; Philippa Davies; Derek Stewart; Christopher J Weir; Amber Young; Nancy J Butcher; Sylwia Bujkiewicz; An-Wen Chan; Gary S Collins; Dalia Dawoud; Martin Offringa; Mario Ouwens; Joseph S Ross; Rod S Taylor; Oriana Ciani
Journal:  BMJ Open       Date:  2022-10-11       Impact factor: 3.006

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.